Cost-effectiveness analysis of routine use of eribulin in patients with metastatic breast cancer in France: A retrospective analysis

MLA

Fernando Bazan, et al. “Cost-Effectiveness Analysis of Routine Use of Eribulin in Patients with Metastatic Breast Cancer in France: A Retrospective Analysis.” Journal of Clinical Oncology, vol. 32, May 2014, p. e11531. EBSCOhost, https://doi.org/10.1200/jco.2014.32.15_suppl.e11531.

APA

Fernando Bazan, Virginie Nerich, Philippe Montcuquet, Laurent Cals, Elsa Curtit, Cristian Villanueva, Xavier Pivot, Antoine Thiery-Vuillemin, Nathalie Meneveau, Marie-Justine Paillard, Loic Chaigneau, Laura Mansi, Erion Dobi, & Hamadi Almotlak. (2014). Cost-effectiveness analysis of routine use of eribulin in patients with metastatic breast cancer in France: A retrospective analysis. Journal of Clinical Oncology, 32, e11531. https://doi.org/10.1200/jco.2014.32.15_suppl.e11531

Chicago

Fernando Bazan, Virginie Nerich, Philippe Montcuquet, Laurent Cals, Elsa Curtit, Cristian Villanueva, Xavier Pivot, et al. 2014. “Cost-Effectiveness Analysis of Routine Use of Eribulin in Patients with Metastatic Breast Cancer in France: A Retrospective Analysis.” Journal of Clinical Oncology 32 (May): e11531. doi:10.1200/jco.2014.32.15_suppl.e11531.